{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:24:33Z","timestamp":1794014673015,"version":"4.8.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Rheumatoid arthritis (RA) is often complicated with chronic lung diseases (CLD), including interstitial lung disease (ILD) and airway disease, which occur as extra-articular manifestations. CLD in RA have been associated with the production of rheumatoid factor (RF), anti-citrullinated peptide antibody (ACPA), or anti-carbamylated protein (CarP) antibody. However, few validation studies have been performed thus far. In the present study, we investigated the association of RF, ACPA, and anti-CarP antibodies with RA complicated with CLD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sera from RA patients with or without CLD were collected. The levels of serum RF, RF immunoglobulin A (IgA), ACPA IgG, ACPA IgA, and ACPA secretory component (SC) were measured using enzyme-linked immunosorbent assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The comparison of RA patients with and without CLD showed that RF IgA was associated with ILD (mean\u2009\u00b1\u2009standard deviation: 206.6\u2009\u00b1\u2009400.5 vs. 95.0\u2009\u00b1\u2009523.1\u2009U\/ml, respectively,<jats:italic>P<\/jats:italic>\u2009=\u20091.13\u2009\u00d7\u200910<jats:sup>\u2212\u20098<\/jats:sup>), particularly usual interstitial pneumonia (UIP) (263.5\u2009\u00b1\u2009502.0\u2009U\/ml,<jats:italic>P<\/jats:italic>\u2009=\u20091.00\u2009\u00d7\u200910<jats:sup>\u2212\u20097<\/jats:sup>). ACPA SC was associated with RA complicated with ILD (mean\u2009\u00b1\u2009standard deviation: 8.6\u2009\u00b1\u200925.1 vs. 2.3\u2009\u00b1\u20093.4\u2009U\/ml, respectively,<jats:italic>P<\/jats:italic>\u2009=\u20090.0003), particularly nonspecific interstitial pneumonia (NSIP) (10.7\u2009\u00b1\u200931.5\u2009U\/ml,<jats:italic>P<\/jats:italic>\u2009=\u20090.0017). Anti-CarP antibodies were associated with RA complicated with ILD (0.042\u2009\u00b1\u20090.285 vs. 0.003\u2009\u00b1\u20090.011\u2009U\/ml, respectively,<jats:italic>P<\/jats:italic>\u00a0=\u20091.04X10<jats:sup>\u2212\u200911<\/jats:sup>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>RF IgA and ACPA SC in RA were associated with UIP and NSIP, respectively, suggesting different specificities in patients with RA. Anti-CarP antibodies were associated with ILD in RA. These results may help elucidate the different pathogeneses of UIP and NSIP in RA.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12891-021-04985-0","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T14:04:44Z","timestamp":1642514684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Serum rheumatoid factor IgA, anti-citrullinated peptide antibodies with secretory components, and anti-carbamylated protein antibodies associate with interstitial lung disease in rheumatoid arthritis"],"prefix":"10.1186","volume":"23","author":[{"given":"Shomi","family":"Oka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Komiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Saisho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norie","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoshi","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Tohma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"issue":"1","key":"4985_CR1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1378\/chest.93.1.114","volume":"93","author":"M Hakala","year":"1988","unstructured":"Hakala M. Poor prognosis in patients with rheumatoid arthritis hospitalized for interstitial lung fibrosis. Chest. 1988;93(1):114\u20138.","journal-title":"Chest"},{"issue":"2","key":"4985_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/03009740310004621","volume":"33","author":"C Turesson","year":"2004","unstructured":"Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol. 2004;33(2):65\u201372.","journal-title":"Scand J Rheumatol"},{"issue":"8","key":"4985_CR3","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1093\/rheumatology\/keq035","volume":"49","author":"G Koduri","year":"2010","unstructured":"Koduri G, Norton S, Young A, Cox N, Davies P, Devlin J, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology. 2010;49(8):1483\u20139.","journal-title":"Rheumatology"},{"issue":"5","key":"4985_CR4","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1183\/09031936.97.10051072","volume":"10","author":"A Vergnenegre","year":"1997","unstructured":"Vergnenegre A, Pugnere N, Antonini MT, Arnaud M, Melloni B, Treves R, et al. Airway obstruction and rheumatoid arthritis. Eur Respir J. 1997;10(5):1072\u20138.","journal-title":"Eur Respir J"},{"issue":"6","key":"4985_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/rheumatology\/36.6.689","volume":"36","author":"DR Swinson","year":"1997","unstructured":"Swinson DR, Symmons D, Suresh U, Jones M, Booth J. Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis. Br J Rheumatol. 1997;36(6):689\u201391.","journal-title":"Br J Rheumatol"},{"issue":"11","key":"4985_CR6","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.rmed.2012.07.006","volume":"106","author":"S Mori","year":"2012","unstructured":"Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med. 2012;106(11):1591\u20139.","journal-title":"Respir Med"},{"issue":"3","key":"4985_CR7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1080\/14397595.2019.1621462","volume":"30","author":"T Kakutani","year":"2020","unstructured":"Kakutani T, Hashimoto A, Tominaga A, Kodama K, Nogi S, Tsuno H, et al. Related factors, increased mortality and causes of death in patients with rheumatoid arthritis-associated interstitial lung disease. Mod Rheumatol. 2020;30(3):458\u201364.","journal-title":"Mod Rheumatol"},{"issue":"12","key":"4985_CR8","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1136\/thoraxjnl-2016-208932","volume":"71","author":"EJ Bernstein","year":"2016","unstructured":"Bernstein EJ, Barr RG, Austin JHM, Kawut SM, Raghu G, Sell JL, et al. Rheumatoid arthritis-associated autoantibodies and subclinical interstitial lung disease: the multi-ethnic study of atherosclerosis. Thorax. 2016;71(12):1082\u201390.","journal-title":"Thorax"},{"issue":"2","key":"4985_CR9","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1136\/rmdopen-2020-001278","volume":"6","author":"V Joshua","year":"2020","unstructured":"Joshua V, Hensvold AH, Reynisdottir G, Hansson M, Cornillet M, Nogueira L, et al. Association between number and type of different ACPA fine specificities with lung abnormalities in early, untreated rheumatoid arthritis. RMD Open. 2020;6(2):2020\u2013001278.","journal-title":"RMD Open"},{"issue":"7","key":"4985_CR10","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.3899\/jrheum.131341","volume":"41","author":"J Zhu","year":"2014","unstructured":"Zhu J, Zhou Y, Chen X, Li J. A metaanalysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity. J Rheumatol. 2014;41(7):1282\u20139.","journal-title":"J Rheumatol"},{"issue":"6","key":"4985_CR11","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.chest.2019.12.005","volume":"157","author":"JJ Solomon","year":"2020","unstructured":"Solomon JJ, Matson S, Kelmenson LB, Chung JH, Hobbs SB, Rosas IO, et al. IgA antibodies directed against Citrullinated protein antigens are elevated in patients with idiopathic pulmonary fibrosis. Chest. 2020;157(6):1513\u201321.","journal-title":"Chest"},{"issue":"4","key":"4985_CR12","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1093\/rheumatology\/kez377","volume":"59","author":"K Roos Ljungberg","year":"2020","unstructured":"Roos Ljungberg K, Joshua V, Skogh T, Eklund A, Sk\u00f6ld CM, Karimi R, et al. Secretory anti-citrullinated protein antibodies in serum associate with lung involvement in early rheumatoid arthritis. Rheumatology (Oxford). 2020;59(4):852\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"4985_CR13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4049\/jimmunol.105.1.43","volume":"105","author":"RH Waldman","year":"1970","unstructured":"Waldman RH, Mach JP, Stella MM, Rowe DS. Secretory IgA in human serum. J Immunol. 1970;105(1):43\u20137.","journal-title":"J Immunol"},{"issue":"2","key":"4985_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1365-2249.2008.03616.x","volume":"152","author":"JW Eijgenraam","year":"2008","unstructured":"Eijgenraam JW, Oortwijn BD, Kamerling SW, de Fijter JW, van den Wall Bake AW, Daha MR, et al. Secretory immunoglobulin a (IgA) responses in IgA nephropathy patients after mucosal immunization, as part of a polymeric IgA response. Clin Exp Immunol. 2008;152(2):227\u201332.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"4985_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1136\/annrheumdis-2018-213724","volume":"78","author":"MAM van Delft","year":"2019","unstructured":"van Delft MAM, van der Woude D, Toes REM, Trouw LA. Secretory form of rheumatoid arthritis-associated autoantibodies in serum are mainly of the IgM isotype, suggesting a continuous reactivation of autoantibody responses at mucosal surfaces. Ann Rheum Dis. 2019;78(1):146\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4985_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2019-216709","volume":"79","author":"R Castellanos-Moreira","year":"2020","unstructured":"Castellanos-Moreira R, Rodr\u00edguez-Garc\u00eda SC, Gomara MJ, Ruiz-Esquide V, Cuervo A, Casafont-Sol\u00e9 I, et al. Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease. Ann Rheum Dis. 2020;79(5):587\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4985_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315\u201324.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"4985_CR18","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569\u201381.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"4985_CR19","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/rheumatology\/kew025","volume":"55","author":"S Oka","year":"2016","unstructured":"Oka S, Furukawa H, Shimada K, Sugii S, Hashimoto A, Komiya A, et al. Association of Human Leukocyte Antigen Alleles with chronic lung diseases in rheumatoid arthritis. Rheumatology (Oxford). 2016;55(7):1301\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"599794","key":"4985_CR20","doi-asserted-by":"publisher","first-page":"599794","DOI":"10.3389\/fmed.2020.599794","volume":"7","author":"H Furukawa","year":"2020","unstructured":"Furukawa H, Oka S, Shimada K, Okamoto A, Hashimoto A, Komiya A, et al. Serum Metabolomic profiling in rheumatoid arthritis patients with interstitial lung disease: a case-control study. Front Med (Lausanne). 2020;7(599794):599794.","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"4985_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/jama.1949.02900430001001","volume":"140","author":"O Steinbrocker","year":"1949","unstructured":"Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140(8):659\u201362.","journal-title":"J Am Med Assoc"},{"issue":"1","key":"4985_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/art.21575","volume":"54","author":"L Klareskog","year":"2006","unstructured":"Klareskog L, Stolt P, Lundberg K, K\u00e4llberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38\u201346.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"4985_CR23","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/ard.2009.120899","volume":"70","author":"H K\u00e4llberg","year":"2011","unstructured":"K\u00e4llberg H, Ding B, Padyukov L, Bengtsson C, R\u00f6nnelid J, Klareskog L, et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis. 2011;70(3):508\u201311.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4985_CR24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s13075-016-1140-9","volume":"18","author":"S Turunen","year":"2016","unstructured":"Turunen S, Huhtakangas J, Nousiainen T, Valkealahti M, Melkko J, Risteli J, et al. Rheumatoid arthritis antigens homocitrulline and citrulline are generated by local myeloperoxidase and peptidyl arginine deiminases 2, 3 and 4 in rheumatoid nodule and synovial tissue. Arthritis Res Ther. 2016;18(1):239.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"4985_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13075-015-0520-x","volume":"17","author":"EB Lugli","year":"2015","unstructured":"Lugli EB, Correia RE, Fischer R, Lundberg K, Bracke KR, Montgomery AB, et al. Expression of citrulline and homocitrulline residues in the lungs of non-smokers and smokers: implications for autoimmunity in rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):9.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"4985_CR26","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/rheumatology\/kex520","volume":"57","author":"A Alunno","year":"2018","unstructured":"Alunno A, Bistoni O, Pratesi F, La Paglia GMC, Puxeddu I, Migliorini P, et al. Anti-citrullinated alpha enolase antibodies, interstitial lung disease and bone erosion in rheumatoid arthritis. Rheumatology (Oxford). 2018;57(5):850\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"4985_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.clim.2019.01.001","volume":"200","author":"Y Liu","year":"2019","unstructured":"Liu Y, Liu C, Li L, Zhang F, Li Y, Zhang S. High levels of antibodies to citrullinated \u03b1-enolase peptide-1 (CEP-1) identify erosions and interstitial lung disease (ILD) in a Chinese rheumatoid arthritis cohort. Clin Immunol. 2019;200:10\u20135.","journal-title":"Clin Immunol"},{"issue":"4","key":"4985_CR28","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/art.37881","volume":"65","author":"L Harlow","year":"2013","unstructured":"Harlow L, Rosas IO, Gochuico BR, Mikuls TR, Dellaripa PF, Oddis CV, et al. Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum. 2013;65(4):869\u201379.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"4985_CR29","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/art.40900","volume":"71","author":"BR England","year":"2019","unstructured":"England BR, Duryee MJ, Roul P, Mahajan TD, Singh N, Poole JA, et al. Malondialdehyde-acetaldehyde adducts and antibody responses in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2019;71(9):1483\u201393.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"4985_CR30","doi-asserted-by":"publisher","first-page":"e35296","DOI":"10.1371\/journal.pone.0035296","volume":"7","author":"J Sokolove","year":"2012","unstructured":"Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. Plos One. 2012;7(5):e35296.","journal-title":"Plos One"},{"issue":"8","key":"4985_CR31","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1136\/annrheumdis-2012-203160","volume":"73","author":"JT Giles","year":"2014","unstructured":"Giles JT, Danoff SK, Sokolove J, Wagner CA, Winchester R, Pappas DA, et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis. 2014;73(8):1487\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4985_CR32","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/cei.12769","volume":"184","author":"C Sandin","year":"2016","unstructured":"Sandin C, Eriksson P, Segelmark M, Skogh T, Kastbom A. IgA- and SIgA anti-PR3 antibodies in serum versus organ involvement and disease activity in PR3-ANCA-associated vasculitis. Clin Exp Immunol. 2016;184(2):208\u201315.","journal-title":"Clin Exp Immunol"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04985-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-021-04985-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04985-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T11:52:51Z","timestamp":1674474771000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-021-04985-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4985"],"URL":"https:\/\/doi.org\/10.1186\/s12891-021-04985-0","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"assertion":[{"value":"26 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HF has the following conflicts, and the following funders are supported wholly or in part by the indicated pharmaceutical companies. The Japan Research Foundation for Clinical Pharmacology is run by Daiichi Sankyo, the Takeda Science Foundation is supported by an endowment from Takeda Pharmaceutical Company and the Nakatomi Foundation was established by Hisamitsu Pharmaceutical Co., Inc. The Daiwa Securities Health Foundation was established by Daiwa Securities Group Inc. and Mitsui Sumitomo Insurance Welfare Foundation was established by Mitsui Sumitomo Insurance Co., Ltd. HF was supported by research grants from Bristol-Myers Squibb Co. HF received honoraria from Ajinomoto Co., Inc., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Pfizer Japan Inc., and Takeda Pharmaceutical Company, Luminex Japan Corporation Ltd., and Ayumi Pharmaceutical Corporation. ST was supported by research grants from nine pharmaceutical companies: Abbott Japan Co., Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Merck Sharp and Dohme Inc., Pfizer Japan Inc., Takeda Pharmaceutical Company Limited, and Teijin Pharma Limited. ST received honoraria from Asahi Kasei Pharma Corporation, Astellas Pharma Inc., AbbVie GK., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Pfizer Japan Inc. The other authors have no financial or commercial conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}